Literature DB >> 18632781

Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.

N Grytten Torkildsen1, S A Lie, J H Aarseth, H Nyland, K M Myhr.   

Abstract

BACKGROUND: Survival time among patients with multiple sclerosis (MS) has varied considerably according to previous reports.
OBJECTIVES: Survival and cause of death were analyzed among all patients with MS (878) with onset of MS in Hordaland County, Western Norway during 1953-2003, of whom 198 were dead at follow-up on January 1, 2005.
METHODS: Standardized mortality ratios (SMRs) and relative mortality ratios (RMRs) were calculated based on observed mortality in MS and expected mortality.
RESULTS: Median survival from onset was 41 years versus 49 years in the corresponding population, and mortality (SMR) was 2.7-fold increased in MS. The median survival was 43 years among women and 36 years among men, but women had higher relative mortality, when compared with the corresponding population, than men (RMR = 1.40). The median survival time was 45 years among young-onset patients (21-30 years) and 23 years among older-onset patients (51-60 years), but young-onset patients had higher relative mortality than older-onset patients, as shown by a significant reduction by 10-year interval of age at onset (RMR = 0.65). Median survival from onset was longer (43 years) among relapsing-remitting MS than primary progressive MS ([PPMS]; 49 years), and the relative mortality was higher in the PPMS group, (RMR = 1.55). According to death certificates, 57% died from MS.
CONCLUSION: Female patients and patients with young onset had longer median time to death but higher relative risk of dying compared with the corresponding population. PPMS had both shorter median time to death from onset and a higher relative risk of dying.

Entities:  

Mesh:

Year:  2008        PMID: 18632781     DOI: 10.1177/1352458508093890

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  26 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Physical activity and self-reported cardiovascular comorbidities in persons with multiple sclerosis: evidence from a cross-sectional analysis.

Authors:  Robert W Motl; Bo Fernhall; Edward McAuley; Gary Cutter
Journal:  Neuroepidemiology       Date:  2011-05-20       Impact factor: 3.282

Review 3.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

4.  Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Authors:  D S Goodin; A T Reder; G C Ebers; G Cutter; M Kremenchutzky; J Oger; D Langdon; M Rametta; K Beckmann; T M DeSimone; V Knappertz
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

5.  Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008.

Authors:  Ching-Piao Tsai; Charles Tzu-Chi Lee
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

6.  Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting.

Authors:  Meheroz H Rabadi; Christopher E Aston
Journal:  Int J MS Care       Date:  2017 Sep-Oct

7.  Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database.

Authors:  Frank R Ernst; Jennifer Pocoski; Gary Cutter; David W Kaufman; Dirk Pleimes
Journal:  Int J MS Care       Date:  2016 May-Jun

8.  The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.

Authors:  Douglas S Goodin
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

Review 9.  Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat.

Authors:  Mark Walterfang; Yin-Hsiu Chien; Jackie Imrie; Derren Rushton; Danielle Schubiger; Marc C Patterson
Journal:  Orphanet J Rare Dis       Date:  2012-10-06       Impact factor: 4.123

10.  Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.

Authors:  Douglas S Goodin; George C Ebers; Gary Cutter; Stuart D Cook; Timothy O'Donnell; Anthony T Reder; Marcelo Kremenchutzky; Joel Oger; Mark Rametta; Karola Beckmann; Volker Knappertz
Journal:  BMJ Open       Date:  2012-11-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.